share_log

Vext Announces Financial Results for Q2 2024

Vext Announces Financial Results for Q2 2024

Vext宣佈2024年第二季度的財務業績
newsfile ·  08/20 18:30
  • Revenue of $8.4 million; Adjusted EBITDA1 of $1.1 million.
  • With one of the largest footprints in Ohio amongst publicly traded peers, Vext is well-positioned to grow revenue and cash flow from operations following the August 6th launch of the adult-use program in the state.
  • Vext's Ohio network currently includes a Tier 1 cultivation facility, a manufacturing facility, and two operating retail dispensaries. Upon closing of previously announced acquisitions2 and completion of additional licensing under state law for the Tier 1 cultivation facility, Vext expects reaching the state dispensary license cap in 2024.
  • 營業收入840萬美元;調整後的EBITDA1爲110萬美元。
  • 在公開交易的同行中,維克斯州內覆蓋面最大之一,全面考慮到即將於8月6日推出該州的成年人項目,該公司有望增加收入和經營現金流量。
  • 目前,維克斯在俄亥俄州擁有一座一流的種植設施、一座製造設施和兩個經營的零售藥店。預計在此前宣佈的收購完成並完成一級種植設施的額外許可後,維克斯將於2024年達到州藥店許可證上限。

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2024) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("VEXT" or the "Company"), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today reported its financial results for the period ended June 30, 2024. All currency references used in this news release are in U.S. currency unless otherwise noted.

加拿大溫哥華--(Newsfile Corp. - 2024年8月20日) - 維克斯科技有限公司 (CSE: VEXT) (OTCQX: VEXTF) ("VEXT"或"公司"),一家總部位於美國的大麻運營商,在亞利桑那州和俄亥俄州都有垂直的業務運營,今天公佈了其截至2024年6月30日的財務業績。本新聞稿中使用的所有貨幣參考數據均爲美元。

Summary Financial Results

財務業績總結


Q2 2024 Q1 2024 Q2 2023
Revenue $8,426,928 $8,390,023 $9,187,122
EBITDA1 $171,309 ($2,285,845) $2,264,980
Adjusted EBITDA1 $1,084,234 $1,957,074 $1,049,115
Adjusted EBITDA Margin (%)1 12.9% 23.3% 11.4%

2024年第二季度 2024年第一季度 ("Q1 2024") 2023年第二季度
營業收入 $8,426,928 $8,390,023 $9,187,122
EBITDA1 $171,309 ($2,285,845) $2,264,980
調整後的EBITDA1 $1,084,234 $1,957,074 $1,049,115
調整後的EBITDA利潤率 (%)1 12.9% 23.3% 11.4%

Management Commentary

管理評論

Eric Offenberger, CEO of Vext, commented, "The launch of adult-use sales in Ohio after quarter-end marks a significant milestone for Vext. Over two years of preparation and operational experience in the state have positioned us well for this transition and we're pleased with the initial results. We view Ohio as one of the most promising adult-use markets in the U.S. and look forward to the opportunities it presents for both the state and Vext."

維克斯的首席執行官埃裏克·奧芬伯格(Eric Offenberger)評論道:「8月底結束後的成年人銷售啓動標誌着維克斯的一個重要里程碑。在該州超過兩年的準備和運營經驗使我們在這個過渡期的位置處於優勢,並且我們對初步結果感到滿意。我們認爲俄亥俄州是美國最有前途的成年人市場之一,並期待它爲該州和維克斯帶來的機會。」

"The first half of the year continued to present challenges for consumer-facing companies, regardless of sector and geographic concentration. I'm proud of our team's efforts to continue driving traffic in this environment through targeted promotions on a wide range of value-based products. For the remainder of 2024, we anticipate improved performance through our focus on seamlessly transitioning our Ohio dispensaries to serve both medical and adult-use markets, enhancing efficiency in our Arizona operations, and exploring growth opportunities across our footprint, which we expect will lead to increasing cash flow, and solid long-term returns for our shareholders," added Mr. Offenberger.

埃裏克·奧芬伯格先生補充說:「今年上半年繼續面對着消費者面對的各種挑戰,無論是在哪個領域和地理範圍內。我爲我們的團隊在這個環境下通過針對廣泛的價值產品的有針對性的促銷活動繼續推動流量而感到驕傲。在2024年的餘下時間裏,我們預計將通過重點關注順利過渡我們的俄亥俄州藥店爲醫療和成年人市場服務、增強我們亞利桑那州業務的效率和探索我們的業務範圍內的增長機會,從而增加現金流量併爲我們的股東帶來穩健的長期回報。」

Summary of Recent Announcements

最新公告摘要

  • On August 2, 2024, the Company announced that it had secured Certificates of Operation for the dual licensing of its cultivation and manufacturing facility as well as its operated dispensaries in Jackson and Columbus and had received approval from the Ohio Division of Cannabis Control to begin selling adult-use cannabis on Tuesday, August 6, 2024.
  • 2024年8月2日,該公司宣佈已獲得其種植和製造設施的雙重許可證,以及傑克遜和哥倫布的經營藥店的許可證,已獲得俄亥俄州大麻管制部門的批准,開始在2024年8月6日星期二開始銷售成人用大麻。

Vext Announces Board Changes

維克斯公佈董事會變更

The Company announced today that Jason Thai Nguyen has stepped down as the Chairman of the Board of Directors (the "Board"), effective August 20, 2024. Mr. Nguyen will retain his position as a Director of Vext. The Company is also pleased to report that the Board has appointed Mark W. Opzoomer, a current independent member of the Board, as non-executive Chairman of the Board, with immediate effect.

該公司今天宣佈,Jason Thai Nguyen已於2024年8月20日辭去董事會主席職務。Nguyen先生將繼續擔任維克斯的董事。同時,該公司還高興地宣佈,董事會已任命董事會獨立成員Mark W. Opzoomer爲非執行董事會主席,立即生效。

Eric Offenberger, CEO of Vext, noted, "On behalf of Vext and its Board, I would like to thank Thai for his vision, contributions and longstanding commitment during his tenure as Chairman. We are pleased that he will continue to provide his valuable insights as a director. We are equally pleased to have Mark step into the role of Chairman. Having already been a key member of our Board, his deep understanding of our business and dedication to our strategic goals have been evident. I am confident that, under his leadership, Vext will continue to drive shareholder value as we enter the next phase of growth with the launch of adult-use sales in Ohio."

維克斯首席執行官Eric Offenberger指出:「我謹代表維克斯及其董事會,感謝Thai在擔任主席期間的遠見卓識、貢獻和長期承諾。我們很高興他將繼續作爲一名董事爲我們提供有價值的見解。我們也很高興Mark接任董事會主席職務。其作爲我們董事會的核心成員之一,他對我們業務的深入了解和爲我們的戰略目標而奮鬥的決心顯而易見。我相信,在他的領導下,維克斯將在俄亥俄州的成年人銷售市場啓動的下一階段繼續推動股東價值。」

Q2 2024 Financial Results Conference Call

2024年第二季度業績電話會議

Vext will host a conference call and webcast on Tuesday, August 20, 2024, at 08:00 a.m. ET. to discuss its second quarter 2024 financial results.

維克斯將於2024年8月20日星期二上午08:00舉行電話會議和網絡直播,討論其2024年第二季度財務業績。

Date: August 20, 2024 | Time: 8:00 am E.T.
Participant Dial-in: +1-647-484-8814 or 1-844-763-8274
Replay Dial-in: +1-412-317-0088 or 1-855-669-9658
Conference ID: 10191819
Playback #: 1766292 (Expires on September 3, 2024)

日期:2024年8月20日|時間:上午8:00美國東部時間。
參會撥號:+1-647-484-8814或1-844-763-8274。
重播撥號:+1-412-317-0088或1-855-669-9658。
會議ID:10191819。
播放號碼:1766292(有效期爲2024年9月3日)。

Listen to webcast:

收聽網絡直播:

For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com.
Non-IFRS Financial Measures

查看更多詳情請瀏覽Vext的投資者網站或聯繫投資者關係團隊investors@vextscience.com。
非IFRS財務指標

This news release contains certain "non-IFRS financial measures" (equivalent to "non-GAAP financial measures", as such term is defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112")), "non-IFRS ratios" (equivalent to "non-GAAP ratios", as such term is defined in NI 52-112), including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA margin". These financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA margin" as Adjusted EBITDA divided by Revenue.

本新聞稿包含某些「非IFRS財務指標」(相當於《52-112號國家儀器——非GAAP和其他財務指標披露》定義下的「非GAAP財務指標」或「非IFRS比率」(相當於NI 52-112下的「非GAAP比率」)),包括「EBITDA」、「調整後的EBITDA」和「調整後的EBITDA利潤率」。這些財務指標在IFRS下沒有標準化定義,也不是按照IFRS計算或呈現,可能與其他公司呈現的類似指標不可比較。公司將EBITDA定義爲利潤之前的利息、稅、折舊和攤銷費用。公司將「調整後的EBITDA」定義爲報告的運營淨收入(虧損),在利息和稅前進行調整,以排除特殊項目、非經常性項目、其他非現金項目(包括股權激勵支出、折舊和攤銷費用、外匯和收購相關成本等,如果適用的話)。公司將「調整後的EBITDA利潤率」定義爲調整後的EBITDA除以營業收入。

The Company has provided these financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.

公司提供這些財務指標作爲補充信息,並且需要與按照IFRS計算和呈現的財務指標一起考慮。公司認爲這些補充財務指標爲分析業務運行績效提供有價值的額外指標。這些補充財務指標不應被視爲優越、替代或替代品,只應與此處呈現的IFRS財務指標一起考慮。

The following information provides reconciliations of the non-IFRS financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.

以下信息提供了本文中介紹的非IFRS財務指標與按照IFRS計算和呈現的最直接可比財務指標之間的調節。


Q2 2024 Q1 2024 Q2 2023
Revenue $ 8,426,928 $ 8,390,023 $ 9,187,122
Net Income after taxes $ (4,390,035) $ (6,333,412) $ 535,454
Interest (Net) 801,832 800,680 1,010,812
Income Taxes (127,244) (340,522) (1,141,064)
Depreciation & Amortization 3,886,756 3,587,409 1,859,779
EBITDA $ 171,309 $ (2,285,845) $ 2,264,980
Share-based compensation 233,868 13,065 68,862
Accretion - - (6,004)
Share (Profit) / Loss on JVs 118,370 162,916 13,854
(Gain)/Loss on Asset Disposal - 1,444 -
Refinance of loan payable - - -
Loan costs WPCU loan - - 342
FV of WPCU loan (104,150) 460,870 219,518
Loan costs EWB amortized 44,827 44,286 43,969
FV of APP1803 option - 2,022,211 -
RSU Taxes - 4,199 4,274
Foreign Exchange (910) (559) 310
ERC tax credit - - (1,680,793)
Relative FV adjustment to inventory - - -
Change in FV of Biological 227,503 604,982 119,802
FV increment on acquired inventory sold 393,417 929,505 -
Gain on acquisition of control and bargain purchase - - -
Reserves on Notes Receivable and Investments in Joint Operations - - -
Executive Chairman Severance - - -
Adjusted EBITDA $ 1,084,234 $ 1,957,074 $ 1,049,115
Adjusted EBITDA Margin (%)1 12.9% 23.3% 11.4%

2024年第二季度 2024年第一季度 ("Q1 2024") 2023年第二季度
營業收入 $ 8,426,928 $ 8,390,023 $ 9,187,122
淨利潤稅後 $ (4,390,035) $ (6,333,412) $ 535,454
利息(淨) 801,832 800,680 1,010,812
所得稅 (127,244) (340,522) (1,141,064)
折舊與攤銷 3,886,756 3,587,409 1,859,779
EBITDA $ 171,309 $ (2,285,845) $ 2,264,980
股權酬金 233,868 13,065 68,862
增值 - - (6,004)
股份(利潤)/ 損失在合營企業 118,370 162,916 13,854
資產處置的收益/損失 - 1,444 -
償還應付貸款 - - -
WPCU貸款成本 - - 342
WPCU貸款的公允價值 (104,150) 460,870 219,518
EWB分期攤銷的借款成本 44,827 44,286 43,969
APP1803期權的公允價值 - 2,022,211 -
RSU稅費 - 4,199 4,274
匯率期貨 (910) (559) 310
ERC稅收抵免額 - - (1,680,793)
庫存的相對公允價值調整 - - -
生物板塊公允價值變動 227,503 604,982 119,802
銷售收購庫存增值 393,417 929,505 -
控制權收購收益和商譽溢價 - - -
應收票據和合營企業投資準備金 - - -
執行主席遣散費 - - -
調整後的EBITDA $ 1,084,234 $ 1,957,074 $ 1,049,115
1.調整後的EBITDA利潤率(%) 12.9% 23.3% 11.4%

About VEXT Science, Inc.

關於VEXT科技公司

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.

Vext Science, Inc.是一家總部位於美國的大麻股運營商,在亞利桑那州和俄亥俄州擁有垂直運營。Vext的專業知識覆蓋從種植到在關鍵市場的零售。總部位於亞利桑那州的Vext擁有和經營先進的種植設施、完全建成的製造設施以及亞利桑那州和俄亥俄州的藥房。公司製造Vapen,是亞利桑那州領先的THC濃縮、食品和精餾煙彈品牌之一。該公司的獲獎產品系列是由Vext的內部高質量花材創建並在亞利桑那州和俄亥俄州以及Vext在其他州的合作伙伴展開銷售。Vext的領導團隊具有建立和運營盈利多州業務的實證業績,該公司自2016年以來一直經營盈利。該公司的主要重點是繼續在亞利桑那州和俄亥俄州的核心州增長,彙集尖端科學、製造和營銷,爲客戶提供可靠和有價值的客戶體驗,同時創造股東價值。

Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at and connect with Vext on Twitter/X and LinkedIn.

Vext Science,Inc。的股票在加拿大證券交易所上市,代碼爲VEXT,在OTCQX市場上交易,代碼爲VEXTF。了解更多信息並與Vext在 Twitter/X 和 LinkedIn 上取得聯繫。

For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands

有關Vapen品牌的更多詳情,請訪問:
Vapen網站: VapenBrands.com
Instagram: @vapen
Facebook:@vapenbrands

Forward Looking Statements

前瞻性聲明

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

本新聞稿中的前瞻性聲明受到有關Vext在此處和在加拿大證券監管機構的定期文件中披露的具體因素所涉及的各種風險和不確定性的影響。當本新聞稿中使用「將,可能,計劃,估計,期望,意圖,可以,潛在,相信,應該」和類似表達時,即爲前瞻性聲明。

Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's transition to serve both the medical and adult-use markets in Ohio and the anticipated results therefrom, market projections of the cannabis industry in the jurisdictions in which the Company operates, statements about the timing and completion of the Ohio Expansion Transaction and the acquisition of additional licenses in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at .

前瞻性聲明可能包括但不限於關於Vext未來發展和業務的聲明,包括但不限於公司在俄亥俄州爲醫療和成年人市場服務的轉型及預期結果,在公司經營的司法管轄區大麻行業的市場預測,關於俄亥俄州擴張交易和獲取更多牌照的計時和完成情況等聲明,所有這些聲明都受到Vext在SE+系統上的持續披露中包含的風險因素的約束。

Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.

雖然Vext已試圖確定可能導致實際結果、績效或成就與前瞻性聲明不同的重要因素,但還可能存在其他因素導致結果、績效或成就不如預期、估計或意圖,包括但不限於:依賴獲得監管批准;從事當前被視爲違反美國聯邦法律的活動;法律變化;依賴管理;需要額外融資;競爭;由於醫用和成年人用大麻行業公衆意見和認知不一致,受阻的市場增長和州份採納;以及監管或政治變化。

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

因爲存在這些風險和不確定性,因此這些前瞻性聲明中預測的結果或事件可能與實際結果或事件有所不同。因此,讀者不應過度依賴前瞻性聲明。本新聞稿中的前瞻性聲明是在本發佈日期做出的。除適用法律要求外,Vext不承擔更新或修訂此類信息的任何意圖或義務,Vext不對此處提及的任何其他公司的披露承擔任何責任。

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.

加拿大證券交易所尚未審核、批准或駁回本新聞發佈的內容。

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

加拿大證券交易所未審查、批准或駁回本新聞發佈內容。

Eric Offenberger
Chief Executive Officer
844-211-3725

Eric Offenberger
首席執行官
844-211-3725

For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851

有關詳細信息:
Jonathan Ross,Vext投資者關係
jon.ross@loderockadvisors.com
416-244-9851

SOURCE: Vext Science, Inc.

來源:Vext科技公司

1 See "Non-IFRS Financial Measures" below for more information regarding Vext's use of non-IFRS financial measures and other reconciliations.

1 有關Vext使用非IFRS財務指標和其他調整的更多信息,請參見下文「非IFRS財務指標」。

2 Vext has executed an asset purchase agreement (as amended from time to time, the "Asset Purchase Agreement"), together with other definitive agreements (together with the Asset Purchase Agreement, the "Definitive Agreements"), with the members of Big Perm's Dispensary Ohio, LLC ("Big Perm") to acquire from Big Perm two cannabis dispensaries located in Ohio, as well as all licenses and assets related to the business of such dispensaries, other than excluded assets, for cash consideration of $7.7 million, subject to adjustments in certain circumstances (the "Ohio Expansion Transaction"). Subject to receipt of required regulatory approvals and other customary conditions precedent, the Company expects that closing of the Ohio Expansion Transaction will occur in 2024.

2 Vext已與Big Perm's Dispensary Ohio, LLC ("Big Perm")的成員簽訂資產購買協議(不時修訂的"資產購買協議"),連同其他明確協議(與資產購買協議一起,即"明確協議"),從Big Perm處收購在俄亥俄州的兩家大麻店,以及與此類店鋪相關的所有牌照和資產(除了排除資產),以770萬美元的現金對價爲代價,在某些情況下進行調整(即"俄亥俄州擴張交易")。根據獲得所需監管批准和其他習慣性的先決條件,該公司預計2024年完成俄亥俄州擴張交易的交割。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論